At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CODX Co-diagnostics Inc.
Trading 12-11 14:52:24 EST
0.3543
-0.0035
-0.98%
High0.3606Low0.3470Vol360.68K
Open0.3500D1 Closing0.3578Amplitude3.80%
Mkt Cap21.57MTradable Cap16.12MTotal Shares60.89M
T/O127.26KT/O Rate0.79%Tradable Shares45.51M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Co-Diagnostics Unveils Portable Cloud-Connected PCR Platform at Boston Conference
Reuters  ·  12-09 22:02
Co-Diagnostics Unveils Portable Cloud-Connected PCR Platform at Boston Conference
CoSara Diagnostics to Showcase New PCR Tests at VIROCON 2025
Reuters  ·  12-09
CoSara Diagnostics to Showcase New PCR Tests at VIROCON 2025
Co-Diagnostics Inc. held shareholder meeting on reverse stock split proposal
Reuters  ·  12-06
Co-Diagnostics Inc. held shareholder meeting on reverse stock split proposal
Co-Diagnostics Initiated at Buy by Maxim Group
Dow Jones  ·  11-26
Co-Diagnostics Initiated at Buy by Maxim Group
Co-Diagnostics Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $1.5
THOMSON REUTERS  ·  11-26
Co-Diagnostics Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $1.5
Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)
TIPRANKS  ·  11-24
Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)
Co-Diagnostics Addresses Tuberculosis Test Adoption at The Union World Conference on Lung Health
Reuters  ·  11-20
Co-Diagnostics Addresses Tuberculosis Test Adoption at The Union World Conference on Lung Health
Co-Diagnostics Initiates Clinical Evaluations For Upper Respiratory Multiplex Point-Of-Care Test On Co-Dx™ Pcr Platform To Support Submission To The U.S. FDA
Reuters  ·  11-20
Co-Diagnostics Initiates Clinical Evaluations For Upper Respiratory Multiplex Point-Of-Care Test On Co-Dx™ Pcr Platform To Support Submission To The U.S. FDA
Co-Diagnostics Launches Clinical Trials for Multiplex PCR Respiratory Test
Reuters  ·  11-18
Co-Diagnostics Launches Clinical Trials for Multiplex PCR Respiratory Test
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ Pcr Platform to Support Submission to the U.S. FDA
THOMSON REUTERS  ·  11-18
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ Pcr Platform to Support Submission to the U.S. FDA
Co-Diagnostics Raises $3.8 Million in Registered Direct Offering
Reuters  ·  11-14
Co-Diagnostics Raises $3.8 Million in Registered Direct Offering
Co-Diagnostics reports Q3 net loss of $5.9 million on $11.4 million in cash and securities
Reuters  ·  11-14
Co-Diagnostics reports Q3 net loss of $5.9 million on $11.4 million in cash and securities
Co-Diagnostics Launches Joint Venture with Arabian Eagle Manufacturing for MENA Expansion
Reuters  ·  11-14
Co-Diagnostics Launches Joint Venture with Arabian Eagle Manufacturing for MENA Expansion
BRIEF-Co-Diagnostics Q3 Revenue USD 100 Thousand
Reuters  ·  11-14
BRIEF-Co-Diagnostics Q3 Revenue USD 100 Thousand
Co-Diagnostics Q3 Adjusted Ebitda USD -6.3 Million
THOMSON REUTERS  ·  11-14
Co-Diagnostics Q3 Adjusted Ebitda USD -6.3 Million
Press Release: Co-Diagnostics Reports Third Quarter 2025 Financial Results
Dow Jones  ·  11-14
Press Release: Co-Diagnostics Reports Third Quarter 2025 Financial Results
Co-Diagnostics Forms Joint Venture in Saudi Arabia
Reuters  ·  11-12
Co-Diagnostics Forms Joint Venture in Saudi Arabia
BRIEF-Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics
Reuters  ·  11-05
BRIEF-Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics
Co-Diagnostics Engages Maxim Group to Explore Strategic Options for CoSara Joint Venture
Reuters  ·  11-05
Co-Diagnostics Engages Maxim Group to Explore Strategic Options for CoSara Joint Venture
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for Its Indian Joint Venture, Cosara Diagnostics Pvt. Ltd
THOMSON REUTERS  ·  11-05
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for Its Indian Joint Venture, Cosara Diagnostics Pvt. Ltd

Introduction

Company Name.
Co-diagnostics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--